Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1106579
Main Authors Edelmann, Jennifer, Malcikova, Jitka, Riches, John C
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.02.2023
Subjects
BCL2 (B-cell lymphoma 2)
BTK - Bruton’s tyrosine kinase
chronic lymphocytic leukemia (CLL)
definition
high-risk
Oncology
TP53
BTK - Bruton’s tyrosine kinase
COVID - 19
chronic lymphocytic leukemia (CLL)
definition
high-risk
BCL2 (B-cell lymphoma 2)
TP53
risk factor
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Tadeusz Robak, Medical University of Lodz, Poland
Reviewed by: Marco Montillo, Niguarda Ca ‘Granda Hospital, Italy; Anna Fink, University Hospital of Cologne, Germany
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1106579